IM Cannabis (IMCC) Cash from Financing Activities (2020 - 2026)
IM Cannabis (IMCC) posted quarterly Cash from Financing Activities of -$680348.9 for Q1 2026, up 66.01% year-over-year from -$409827.0 in Q1 2025, and up 55.29% quarter-over-quarter from -$1.5 million in Q4 2025.
IM Cannabis (IMCC) Cash from Financing Activities (2020 - 2026) Analysis & Trends
IM Cannabis' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$680348.9 for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 66.01% year-over-year to -$680348.9; the TTM figure through Mar 2026 stood at $2.3 million (up 66.38% YoY), while the FY2025 annual figure was $821780.9, down 70.59% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$680348.9, up from -$1.5 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $4.9 million in Q1 2023, with the low at -$3.2 million in Q3 2022.
- The 5-year median for Cash from Financing Activities is $32477.1 (2025), against an average of $806540.5.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities slumped 268.24% in 2022, then surged 10232.79% in 2024.
- IM Cannabis' Cash from Financing Activities stood at $1.4 million in 2022, then tumbled by 101.99% to -$27177.8 in 2023, then soared by 10232.79% to $2.8 million in 2024, then sank by 155.26% to -$1.5 million in 2025, then soared by 55.29% to -$680348.9 in 2026.
- Business Quant data shows IMCC's Cash from Financing Activities at -$680348.9 in Q1 2026, -$1.5 million in Q4 2025, and $4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | IM Cannabis | 549,631.99 | -619,338.18 | 1.09 Mn | 472,070.20 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -680,348.91 |
| Mar 31, 2026 | -680,348.91 |
| Dec 31, 2025 | -1.52 Mn |
| Dec 31, 2025 | -1.52 Mn |
| Sep 30, 2025 | 4.43 Mn |
| Sep 30, 2025 | 4.43 Mn |
| Jun 30, 2025 | 32,477.06 |
| Jun 30, 2025 | 32,477.06 |
| Mar 31, 2025 | -2.00 Mn |
| Mar 31, 2025 | -2.00 Mn |
| Dec 31, 2024 | 2.75 Mn |
| Dec 31, 2024 | 2.75 Mn |
| Sep 30, 2024 | -487,480.52 |
| Sep 30, 2024 | -487,480.52 |
| Jun 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | -632,280.45 |
| Mar 31, 2024 | -632,280.45 |
| Dec 31, 2023 | -27,177.81 |
| Dec 31, 2023 | -27,177.81 |